Midostaurin (BioDeep_00000015022)
代谢物信息卡片
Midostaurin
化学式: C35H30N4O4 (570.226694)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC12C(C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC
InChI: InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1
描述信息
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor
D000970 - Antineoplastic Agents
同义名列表
1 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:63452
- KEGG: C71714
- KEGGdrug: D05029
- PubChem: 9829523
- DrugBank: DB06595
- ChEMBL: CHEMBL608533
- CAS: 120685-11-2
分类词条
相关代谢途径
Reactome(5)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Romain Sechaud, Karen Sinclair, Kai Grosch, Taoufik Ouatas, Dhrubajyoti Pathak. Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML).
Cancer chemotherapy and pharmacology.
2022 Jul; 90(1):19-27. doi:
10.1007/s00280-022-04448-w. [PMID: 35751657] - Amritpal Singh, Aref Al-Kali, Kebede H Begna, Mark R Litzow, Jeremy T Larsen, Taimur Sher, Maymona G Abdelmagid, Faiqa Farrukh, Kaaren K Reichard, Naseema Gangat, Animesh Pardanani, Ayalew Tefferi. Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.
American journal of hematology.
2022 05; 97(5):630-637. doi:
10.1002/ajh.26498. [PMID: 35156231] - Kouhei Yamawaki, Isamu Shiina, Takatsugu Murata, Satoru Tateyama, Yutarou Maekawa, Mariko Niwa, Motoyuki Shimonaka, Koji Okamoto, Toshihiro Suzuki, Toshirou Nishida, Ryo Abe, Yuuki Obata. FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cells.
Scientific reports.
2021 11; 11(1):22678. doi:
10.1038/s41598-021-02221-2. [PMID: 34811450] - Pierantonio Menna, Emanuela Salvatorelli, Maria Ilaria Del Principe, Salvatore Perrone, Livio Pagano, Francesco Marchesi, Giorgio Minotti. Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life.
Chemotherapy.
2021; 66(1-2):47-52. doi:
10.1159/000513989. [PMID: 33677444] - Zhe Wang, Xiaoyu Wang, Yaqin Jia, Hang Yin, Yuyi Feng, Lili Jiang, Jun Cao, Yong Liu. Inhibition of human UDP-glucuronosyltransferase enzymes by midostaurin and ruxolitinib: implications for drug-drug interactions.
Biopharmaceutics & drug disposition.
2020 Jun; 41(6):231-238. doi:
10.1002/bdd.2241. [PMID: 32436276] - Jonathan D Pankow, Guillaume Richard-Carpentier, Naval G Daver, William F Glass, Jaya Kala. Unique case of ANCA-negative pauci-immune necrotizing glomerulonephritis with diffuse alveolar hemorrhage, potentially associated with midostaurin.
CEN case reports.
2020 05; 9(2):147-151. doi:
10.1007/s13730-020-00443-3. [PMID: 31955389] - Robert Mancini, Leslie LaMontagne, Travis Williams, William Kreisle, Finn Petersen. Midostaurin and cyclosporine drug interaction: A case report.
Journal of clinical pharmacy and therapeutics.
2020 Apr; 45(2):384-387. doi:
10.1111/jcpt.13077. [PMID: 31782821] - Benjamin K Tomlinson, Molly M Gallogly, Donna M Kane, Leland Metheny, Hillard M Lazarus, Basem M William, Michael D Craig, Mark J Levis, Brenda W Cooper. A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia.
Clinical lymphoma, myeloma & leukemia.
2020 04; 20(4):226-233.e1. doi:
10.1016/j.clml.2019.10.018. [PMID: 32085993] - Eris Tollkuci, Amanda Seddon, Laura Geswein, Musa Mulseh. Midostaurin administration in two hemodialysis patients.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2019 Jul; 25(5):1285-1288. doi:
10.1177/1078155218801067. [PMID: 30253726] - Animesh Pardanani. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
American journal of hematology.
2019 03; 94(3):363-377. doi:
10.1002/ajh.25371. [PMID: 30536695] - Anne M Filppula, Tiffany M Mustonen, Janne T Backman. In Vitro Screening of Six Protein Kinase Inhibitors for Time-Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drug-Drug Interactions.
Basic & clinical pharmacology & toxicology.
2018 Dec; 123(6):739-748. doi:
10.1111/bcpt.13088. [PMID: 29956478] - Paul W Manley, Giorgio Caravatti, Pascal Furet, Johannes Roesel, Phi Tran, Trixie Wagner, Markus Wartmann. Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy.
Biochemistry.
2018 09; 57(38):5576-5590. doi:
10.1021/acs.biochem.8b00727. [PMID: 30148617] - Mohamad Jawhar, Juliana Schwaab, Manja Meggendorfer, Nicole Naumann, Hans-Peter Horny, Karl Sotlar, Torsten Haferlach, Karla Schmitt, Alice Fabarius, Peter Valent, Wolf-Karsten Hofmann, Nicholas C P Cross, Georgia Metzgeroth, Andreas Reiter. The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.
Haematologica.
2017 06; 102(6):1035-1043. doi:
10.3324/haematol.2017.163964. [PMID: 28255023] - Handan He, Phi Tran, Helen Gu, Vivienne Tedesco, Jin Zhang, Wen Lin, Ewa Gatlik, Kai Klein, Tycho Heimbach. Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug.
Drug metabolism and disposition: the biological fate of chemicals.
2017 05; 45(5):540-555. doi:
10.1124/dmd.116.072744. [PMID: 28270565] - Zeenat Mirza, Hans-Juergen Schulten, Hasan Ma Farsi, Jaudah A Al-Maghrabi, Mamdooh A Gari, Adeel Ga Chaudhary, Adel M Abuzenadah, Mohammed H Al-Qahtani, Sajjad Karim. Molecular interaction of a kinase inhibitor midostaurin with anticancer drug targets, S100A8 and EGFR: transcriptional profiling and molecular docking study for kidney cancer therapeutics.
PloS one.
2015; 10(3):e0119765. doi:
10.1371/journal.pone.0119765. [PMID: 25789858] - Catherine Dutreix, Sebastien Lorenzo, Yanfeng Wang. Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin.
European journal of clinical pharmacology.
2014 Aug; 70(8):915-20. doi:
10.1007/s00228-014-1675-0. [PMID: 24839948] - Philippe Bourget, Alexandre Amin, Marie-Olivia Chandesris, Fabrice Vidal, Christophe Merlette, Isabelle Hirsch, Laure Cabaret, Ana Carvalhosa, Agnès Mogenet, Laurent Frenzel, Gandhi Damaj, Olivier Lortholary, Olivier Hermine. Liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2014 Jan; 944(?):175-81. doi:
10.1016/j.jchromb.2013.11.003. [PMID: 24316764] - Catherine Dutreix, Florence Munarini, Sebastien Lorenzo, Johannes Roesel, Yanfeng Wang. Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.
Cancer chemotherapy and pharmacology.
2013 Dec; 72(6):1223-34. doi:
10.1007/s00280-013-2287-6. [PMID: 24085261] - Jan Menne, Nelli Shushakova, Janina Bartels, Yulia Kiyan, Robert Laudeley, Hermann Haller, Joon-Keun Park, Matthias Meier. Dual inhibition of classical protein kinase C-α and protein kinase C-β isoforms protects against experimental murine diabetic nephropathy.
Diabetes.
2013 Apr; 62(4):1167-74. doi:
10.2337/db12-0534. [PMID: 23434935] - Adam del Corral, Catherine Dutreix, Alice Huntsman-Labed, Sebastien Lorenzo, Joel Morganroth, Robert Harrell, Yanfeng Wang. Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers.
Cancer chemotherapy and pharmacology.
2012 May; 69(5):1255-63. doi:
10.1007/s00280-012-1825-y. [PMID: 22294470] - Animesh Pardanani. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.
American journal of hematology.
2012 Apr; 87(4):401-11. doi:
10.1002/ajh.23134. [PMID: 22410759] - David K Heidary, George Huang, Diane Boucher, Jianguo Ma, Cornelia Forster, Ron Grey, Jinwang Xu, Michael Arnost, Deborah Choquette, Guanjing Chen, Jie-Hua Zhou, Yung-Mae Yao, Edward D Ball, Mark Namchuk, Robert J Davies, Greg Henkel. VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia.
Journal of medicinal chemistry.
2012 Jan; 55(2):725-34. doi:
10.1021/jm201198w. [PMID: 22221201] - Animesh Pardanani. Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.
American journal of hematology.
2011 Apr; 86(4):362-71. doi:
10.1002/ajh.21982. [PMID: 21442641] - Takashi Sato, Xiaochuan Yang, Steven Knapper, Paul White, B Douglas Smith, Steven Galkin, Donald Small, Alan Burnett, Mark Levis. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.
Blood.
2011 Mar; 117(12):3286-93. doi:
10.1182/blood-2010-01-266742. [PMID: 21263155] - Bénédicte Brounais, Céline Chipoy, Kanji Mori, Céline Charrier, Séverine Battaglia, Paul Pilet, Carl D Richards, Dominique Heymann, Françoise Rédini, Frédéric Blanchard. Oncostatin M induces bone loss and sensitizes rat osteosarcoma to the antitumor effect of Midostaurin in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2008 Sep; 14(17):5400-9. doi:
10.1158/1078-0432.ccr-07-4781. [PMID: 18765531] - Yanfeng Wang, Ophelia Q P Yin, Peter Graf, James C Kisicki, Horst Schran. Dose- and time-dependent pharmacokinetics of midostaurin in patients with diabetes mellitus.
Journal of clinical pharmacology.
2008 Jun; 48(6):763-75. doi:
10.1177/0091270008318006. [PMID: 18508951] - Ophelia Q P Yin, Yanfeng Wang, Horst Schran. A mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjects.
Clinical pharmacokinetics.
2008; 47(12):807-16. doi:
10.2165/0003088-200847120-00005. [PMID: 19026036] - Thomas Illmer, Hans-M Thiede, Christian Thiede, Martin Bornhäuser, Markus Schaich, Eberhard Schleyer, Gerhard Ehninger. A highly sensitive method for the detection of PKC412 (CGP41251) and its metabolites by high-performance liquid chromatography.
Journal of pharmacological and toxicological methods.
2007 Jul; 56(1):23-7. doi:
10.1016/j.vascn.2006.11.005. [PMID: 17395497] - Mark Levis, Patrick Brown, B Douglas Smith, Adam Stine, Rosalyn Pham, Richard Stone, Daniel Deangelo, Ilene Galinsky, Frank Giles, Elihu Estey, Hagop Kantarjian, Pamela Cohen, Yanfeng Wang, Johannes Roesel, Judith E Karp, Donald Small. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.
Blood.
2006 Nov; 108(10):3477-83. doi:
10.1182/blood-2006-04-015743. [PMID: 16857987] - M J Millward, C House, D Bowtell, L Webster, I N Olver, M Gore, M Copeman, K Lynch, A Yap, Y Wang, P S Cohen, J Zalcberg. The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study.
British journal of cancer.
2006 Oct; 95(7):829-34. doi:
10.1038/sj.bjc.6603331. [PMID: 16969355] - Florian Heidel, Fian K Solem, Frank Breitenbuecher, Daniel B Lipka, Stefan Kasper, M H Thiede, Christian Brandts, Hubert Serve, Johannes Roesel, Francis Giles, Eric Feldman, Gerhard Ehninger, Gary J Schiller, Stephen Nimer, Richard M Stone, Yanfeng Wang, Thomas Kindler, Pamela S Cohen, Christoph Huber, Thomas Fischer. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.
Blood.
2006 Jan; 107(1):293-300. doi:
10.1182/blood-2005-06-2469. [PMID: 16150941] - Jason Gotlib, Caroline Berubé, Joseph D Growney, Ching-Cheng Chen, Tracy I George, Christopher Williams, Tomohiro Kajiguchi, Jia Ruan, Stan L Lilleberg, Jeffrey A Durocher, Jack H Lichy, Yanfeng Wang, Pamela S Cohen, Daniel A Arber, Michael C Heinrich, Len Neckers, Stephen J Galli, D Gary Gilliland, Steven E Coutré. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.
Blood.
2005 Oct; 106(8):2865-70. doi:
10.1182/blood-2005-04-1568. [PMID: 15972446] - Nizar J Bahlis, Yanling Miao, Omer N Koc, Kelvin Lee, Lawrence H Boise, Stanton L Gerson. N-benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells.
Leukemia & lymphoma.
2005 Jun; 46(6):899-908. doi:
10.1080/10428190500080595. [PMID: 16019536] - Huige Li, Stephan M Hergert, Stephan C Schäfer, Isolde Brausch, Ying Yao, Qi Huang, Christian Mang, Hans-Anton Lehr, Ulrich Förstermann. Midostaurin upregulates eNOS gene expression and preserves eNOS function in the microcirculation of the mouse.
Nitric oxide : biology and chemistry.
2005 Jun; 12(4):231-6. doi:
10.1016/j.niox.2005.04.001. [PMID: 15890550] - Joseph P Eder, Rocio Garcia-Carbonero, Jeffrey W Clark, Jeffrey G Supko, Thomas A Puchalski, David P Ryan, Pamela Deluca, Antoinette Wozniak, Angela Campbell, John Rothermel, Patricia LoRusso. A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies.
Investigational new drugs.
2004 Apr; 22(2):139-50. doi:
10.1023/b:drug.0000011790.31292.ef. [PMID: 14739662] - Andres Virchis, Kanagasabai Ganeshaguru, Steve Hart, Dylan Jones, Linda Fletcher, Faith Wright, Ranmohan Wickremasinghe, Anthony Man, Katalin Csermak, Thomas Meyer, Doriano Fabbro, Kate Champain, Alan Yap, H Grant Prentice, Atul Mehta. A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C.
The hematology journal : the official journal of the European Haematology Association.
2002; 3(3):131-6. doi:
10.1038/sj.thj.6200165. [PMID: 12111648] - D J Propper, A C McDonald, A Man, P Thavasu, F Balkwill, J P Braybrooke, F Caponigro, P Graf, C Dutreix, R Blackie, S B Kaye, T S Ganesan, D C Talbot, A L Harris, C Twelves. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2001 Mar; 19(5):1485-92. doi:
10.1200/jco.2001.19.5.1485. [PMID: 11230495] - D R Cooper, J E Watson, N Patel, P Illingworth, M Acevedo-Duncan, J Goodnight, C E Chalfant, H Mischak. Ectopic expression of protein kinase CbetaII, -delta, and -epsilon, but not -betaI or -zeta, provide for insulin stimulation of glucose uptake in NIH-3T3 cells.
Archives of biochemistry and biophysics.
1999 Dec; 372(1):69-79. doi:
10.1006/abbi.1999.1472. [PMID: 10562418] - R van Gijn, O van Tellingen, E Haverkate, J J Kettenes-van den Bosch, A Bult, J H Beijnen. Pharmacokinetics and metabolism of the staurosporine analogue CGP 41 251 in mice.
Investigational new drugs.
1999; 17(1):29-41. doi:
10.1023/a:1006260217400. [PMID: 10555120] - A Gescher. Analogs of staurosporine: potential anticancer drugs?.
General pharmacology.
1998 Nov; 31(5):721-8. doi:
10.1016/s0306-3623(98)00069-x. [PMID: 9809468] - N Grosman. Influence of probes for calcium-calmodulin and protein kinase C signalling on the plasma membrane Ca2+-ATPase activity of rat synaptosomes and leukocyte membranes.
Immunopharmacology.
1998 Aug; 40(2):163-71. doi:
10.1016/s0162-3109(98)00042-3. [PMID: 9826030] - I Utz, M Spitaler, M Rybczynska, C Ludescher, W Hilbe, U Regenass, H Grunicke, J Hofmann. Reversal of multidrug resistance by the staurosporine derivatives CGP 41251 and CGP 42700.
International journal of cancer.
1998 Jul; 77(1):64-9. doi:
10.1002/(sici)1097-0215(19980703)77:1<64::aid-ijc11>3.0.co;2-9. [PMID: 9639395] - M Madörin, P van Hoogevest, R Hilfiker, B Langwost, G M Kresbach, M Ehrat, H Leuenberger. Analysis of drug/plasma protein interactions by means of asymmetrical flow field-flow fractionation.
Pharmaceutical research.
1997 Dec; 14(12):1706-12. doi:
10.1023/a:1012171511285. [PMID: 9453057] - M Begemann, S A Kashimawo, Y A Choi, S Kim, K M Christiansen, G Duigou, M Mueller, I Schieren, S Ghosh, D Fabbro, N M Lampen, D F Heitjan, P B Schiff, J N Bruce, I B Weinstein. Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter.
Clinical cancer research : an official journal of the American Association for Cancer Research.
1996 Jun; 2(6):1017-30. doi:
NULL. [PMID: 9816263] - G H Baltuch, V W Yong. Signal transduction for proliferation of glioma cells in vitro occurs predominantly through a protein kinase C-mediated pathway.
Brain research.
1996 Feb; 710(1-2):143-9. doi:
10.1016/0006-8993(95)01395-4. [PMID: 8963653] - R van Gijn, E Havik, E Boven, J B Vermorken, W W ten Bokkel Huinink, O van Tellingen, J H Beijnen. High-performance liquid chromatographic analysis of the new antitumour drug N-benzoylstaurosporine (CGP 41 251) and four potential metabolites in micro-volumes of plasma.
Journal of pharmaceutical and biomedical analysis.
1995 Dec; 14(1-2):165-74. doi:
10.1016/0731-7085(95)01616-3. [PMID: 8833979] - A Fasano, C Fiorentini, G Donelli, S Uzzau, J B Kaper, K Margaretten, X Ding, S Guandalini, L Comstock, S E Goldblum. Zonula occludens toxin modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro.
The Journal of clinical investigation.
1995 Aug; 96(2):710-20. doi:
10.1172/jci118114. [PMID: 7635964] - R van Gijn, O van Tellingen, J J de Clippeleir, M J Hillebrand, E Boven, J B Vermorken, W W ten Bokkel Huinink, S Schwertz, P Graf, J H Beijnen. Analytical procedure for the determination of the new antitumour drug N-benzoylstaurosporine and three potential metabolites in human plasma by reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications.
1995 May; 667(2):269-76. doi:
10.1016/0378-4347(95)00037-j. [PMID: 7663699] - M Bosch, A López-Girona, O Bachs, N Agell. Protein kinase C regulates calmodulin expression in NRK cells activated to proliferate from quiescence.
Cell calcium.
1994 Dec; 16(6):446-54. doi:
10.1016/0143-4160(94)90074-4. [PMID: 7712538] - T van der Bruggen, P T Kok, M Blom, A J Verhoeven, J A Raaijmakers, J W Lammers, L Koenderman. Transient exposure of human eosinophils to the protein kinase C inhibitors CGP39-360, CGP41-251, and CGP44-800 leads to priming of the respiratory burst induced by opsonized particles.
Journal of leukocyte biology.
1993 Dec; 54(6):552-7. doi:
10.1002/jlb.54.6.552. [PMID: 8245706] - T Rochat, C Burkhard, V Finci-Cerkez, P Meda. Oxidative stress causes a protein kinase C-independent increase of paracellular permeability in an in vitro epithelial model.
American journal of respiratory cell and molecular biology.
1993 Nov; 9(5):496-504. doi:
10.1165/ajrcmb/9.5.496. [PMID: 8217190] - . .
.
. doi:
. [PMID: 32353859]